|
|
Andrea Casazza, Veronica Finisguerra, Lorena Capparuccia, Andrea Camperi, Jakub M. Swiercz, Sabrina Rizzolio, Charlotte Rolny, Claus Christensen, Andrea Bertotti, Ivana Sarotto, Mauro Risio, Livio Trusolino, Jurgen Weitz, Martin Schneider, Massimilano Mazzone, Paolo M. Comoglio, Luca Tamagnone
J Clin Invest. 2010;
120(8):2684
doi:10.1172/JCI42118
Abstract |
Full text
| PDF
| Supplemental material

S
emaphorin 3E (Sema3E) is a secreted molecule implicated in axonal path finding and inhibition of developmental and postischemic angiogenesis. Sema3E is also highly expressed in metastatic cancer cells, but its mechanistic role in tumor progression was not understood. Here we show that expression of Sema3E and its receptor Plexin D1 correlates with the metastatic progression of human tumors. Consistent with the clinical data, knocking down endogenous expression of either Sema3E or Plexin D1 in human metastatic carcinoma cells hampered their metastatic potential when injected into mice, while tumor growth was not markedly affected. Conversely, overexpression of exogenous Sema3E in cancer cells increased their invasiveness, transendothelial migration, and metastatic spreading, although it inhibited tumor vessel formation, resulting in reduced tumor growth in mice. The proinvasive and metastatic activity of Sema3E in tumor cells was dependent on transactivation of the Plexin D1–associated ErbB2/Neu oncogenic kinase. In sum, Sema3E–Plexin D1 signaling in cancer cells is crucially implicated in their metastatic behavior and may therefore be a promising target for strategies aimed at blocking tumor metastasis.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(8)
| Title and authors |
Publication |
Year |
More than nervous: The emerging roles of plexins
Nina Perälä, Hannu Sariola, Tiina Immonen
|
Differentiation
|
2012 |
Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform
Andrea Casazza, Boaz Kigel, Federica Maione, Lorena Capparuccia, Ofra Kessler, Enrico Giraudo, Massimiliano Mazzone, Gera Neufeld, Luca Tamagnone
|
EMBO Mol Med
|
2012 |
Plexin-B1 and Semaphorin 4D Cooperate to Promote Perineural Invasion in a RhoA/ROK-Dependent Manner
Nada O. Binmadi, Ying-Hua Yang, Hua Zhou, Patrizia Proia, Yi-Ling Lin, Alfredo M. Batista De Paula, André L. Sena Guimarães, Fabiano O. Poswar, Devaki Sundararajan, John R. Basile
|
Amer J Pathol
|
2012 |
Diverse roles for semaphorin−plexin signaling in the immune system
Hyota Takamatsu, Atsushi Kumanogoh
|
Trends in Immunology
|
2012 |
Exploiting pleiotropic activities of semaphorins as multi-target therapies for cancer
Lidia Moserle, Oriol Casanovas
|
EMBO Mol Med
|
2012 |
Class 3 semaphorins and their receptors in physiological and pathological angiogenesis
Carolyn A. Staton
|
Biochem. Soc. Trans.
|
2011 |
Semaphorin signaling in angiogenesis, lymphangiogenesis and cancer
Atsuko Sakurai, Colleen Doci, J Silvio Gutkind
|
Cell Res
|
2011 |
Semaphorin 3E, an exception to the rule
Michael Klagsbrun, Akio Shimizu
|
J. Clin. Invest.
|
2010 |
|